ZA202309775B - Anti-galectin-9 antibodies and therapeutic uses thereof - Google Patents

Anti-galectin-9 antibodies and therapeutic uses thereof

Info

Publication number
ZA202309775B
ZA202309775B ZA2023/09775A ZA202309775A ZA202309775B ZA 202309775 B ZA202309775 B ZA 202309775B ZA 2023/09775 A ZA2023/09775 A ZA 2023/09775A ZA 202309775 A ZA202309775 A ZA 202309775A ZA 202309775 B ZA202309775 B ZA 202309775B
Authority
ZA
South Africa
Prior art keywords
galectin
solid tumors
antibodies
therapeutic uses
cancer
Prior art date
Application number
ZA2023/09775A
Other languages
English (en)
Inventor
Filipovic Aleksandra
Elenko Eric
Heather Paden
Christopher Korth
Original Assignee
Puretech Lyt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt Inc filed Critical Puretech Lyt Inc
Publication of ZA202309775B publication Critical patent/ZA202309775B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA2023/09775A 2021-04-30 2023-10-19 Anti-galectin-9 antibodies and therapeutic uses thereof ZA202309775B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163182521P 2021-04-30 2021-04-30
US202163193357P 2021-05-26 2021-05-26
US202263313879P 2022-02-25 2022-02-25
PCT/US2022/027127 WO2022232641A1 (en) 2021-04-30 2022-04-29 Anti-galectin-9 antibodies and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ZA202309775B true ZA202309775B (en) 2025-03-26

Family

ID=83847350

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/09775A ZA202309775B (en) 2021-04-30 2023-10-19 Anti-galectin-9 antibodies and therapeutic uses thereof

Country Status (8)

Country Link
US (1) US20240190970A1 (https=)
EP (1) EP4329807A4 (https=)
JP (1) JP2024519450A (https=)
AU (1) AU2022266821A1 (https=)
CA (1) CA3217822A1 (https=)
IL (1) IL308014A (https=)
WO (1) WO2022232641A1 (https=)
ZA (1) ZA202309775B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
AU2020247993A1 (en) * 2019-03-25 2021-11-18 New York University Anti-Galectin-9 antibodies and uses thereof
JP7581238B2 (ja) * 2019-05-01 2024-11-12 ニューヨーク・ユニバーシティ 抗ガレクチン９抗体およびその使用
US20220332832A1 (en) * 2019-08-01 2022-10-20 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
US20240287195A1 (en) * 2020-10-26 2024-08-29 Puretech Lyt, Inc. Anti-galectin-9 antibodies and uses thereof in the treatment of ocular melanoma
WO2022109299A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
US20240043543A1 (en) * 2020-11-20 2024-02-08 New York University Anti-galectin-9 antibodies and therapeutic uses thereof

Also Published As

Publication number Publication date
EP4329807A4 (en) 2025-03-12
CA3217822A1 (en) 2022-11-03
AU2022266821A1 (en) 2023-11-09
US20240190970A1 (en) 2024-06-13
EP4329807A1 (en) 2024-03-06
WO2022232641A1 (en) 2022-11-03
IL308014A (en) 2023-12-01
JP2024519450A (ja) 2024-05-14
AU2022266821A9 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2022009170A (es) Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
BR112019010356A2 (pt) molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
NZ798828A (en) Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
MX2019007801A (es) Tratamiento de cáncer avanzado con expresión de her2.
NO20090450L (no) Tumorterapi med at anti-VEGF antistoff
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
MY190252A (en) Anti-cxcr4 antibodies and antibody-drug conjugates
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
HK1254404A1 (zh) 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
WO2010138803A3 (en) Herv-k antigens, antibodies, and methods
RU2017131430A (ru) Способ лечения рака, ассоциированного с мутацией ras
BR112018072872A2 (pt) compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indol para tratar câncer
MX2011010469A (es) Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
ZA202309775B (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW201129380A (en) Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
RU2016112421A (ru) Протиоопухолевое средство и усилитель противоопухолевого эффекта
WO2007137279A3 (en) Herv-k antigens, antibodies, and methods
UA97400C2 (uk) Посилення ефективності хіміотерапії раку
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
GEP20176805B (en) Conjugated antibodies against ly75 for the treatment of cancer
RU2012139825A (ru) Антагонисты неурегулина и применение их в лечении злокачественного новообразования
BR112022001045A2 (pt) Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
MX2024003797A (es) Conjugados de anticuerpos b7-h4 y farmacos para el tratamiento del cancer.
MX2019009121A (es) Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo.